Cognitive Measures Comparison for Alzheimer's Disease Prevention
(NoMAD Trial)

Recruiting in Palo Alto (17 mi)

+3 other locations

Overseen byTerry E. Goldberg, Ph.D.

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: New York State Psychiatric Institute

No Placebo Group

Trial Summary

What is the purpose of this trial?This protocol focuses on novel measures of cognition and everyday function that have robust psychometrics and reduced practiced effects. They will be deployed in a parallel group study in which participants are randomized to assessment type (novel vs established) and receive serial assessments over a one year period in order to highlight contrasts between novel and established measures.

Eligibility Criteria

This trial is for English-speaking individuals aged 60-85 with memory concerns but no severe cognitive impairment (MMSE score ≥24). They must have a reliable informant and meet certain education-specific memory criteria. Excluded are those with significant neurological diseases, untreated diabetes, active cancer treatment, or using specific antidepressants.

Inclusion Criteria

You need to have a certain score on a memory test based on the number of years you went to school.

I am between 60 and 85 years old and speak English.

If you have memory problems, you can still participate in the study.

+2 more

Exclusion Criteria

I am currently receiving treatment for cancer.

I am not taking antidepressants known for strong anticholinergic effects.

I have been diagnosed with a major psychiatric disorder and/or have a current issue with alcohol or substance use.

+5 more

Participant Groups

The study compares novel cognitive and functional measures designed to prevent Alzheimer's disease against established ones over one year. Participants will be randomly assigned to either the new tests or traditional ones to see which better detects changes in cognition and daily function.

2Treatment groups

Experimental Treatment

Active Control

Group I: Novel measures of cognition and everyday functionExperimental Treatment1 Intervention

No Practice Effects (NPE) cognitive battery Miami Computerized Functional Assessment Scale (CFAS) Participants will receive three serial assessments of the NPE and CFAS over a one year period. Assessments will take place at baseline, week 12, and week 52.

Group II: Established measures of cognition and everyday functionActive Control1 Intervention

Preclinical Alzheimer's Cognitive Composite (PACC) Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Functional Assessment Questionnaire (FAQ). Participants will receive three serial assessments of the PACC, ADAS-Cog and FAQ over a one year period. Assessments will take place at baseline, week 12, and week 52.